Reportlinker Adds Stem Cells - The Hype and the Hope 2010-2025

NEW YORK, June 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cells - The Hype and the Hope 2010-2025

http://www.reportlinker.com/p0210913/Stem-Cells---The-Hype-and-the-Hope-2010-2025.html

Report Details

- what commercial prospects for those technologies in medicine?

In 2010, the stem cells market stands on the brink of technological and commercial breakthroughs, our new study explains. For the first time, pharmaceutical companies are beginning to invest significantly in the drive to create new treatments based on embryonic and adult stem cells. As this research gathers pace, with clinical trials commencing, the potential of stem cells in medicine may relatively soon be fulfilled. Results in animals indicate that stem cells may provide treatment options for a range of disorders and restorative applications including multiple sclerosis, diabetes, Parkinson's disease, Alzheimer's disease, spinal cord injury, blindness, immune system disorders and cardiovascular disease.

Stem Cells - The Hype and the Hope 2010-2025 provides an analytical overview of this burgeoning sector, with technologies and commercial potential discussed and forecasted. The sector will gather momentum as stem cell therapies start to emerge from the R&D pipeline from this decade onwards. In this report we assess the disease areas in which stem cell therapies are most likely to emerge, with overviews of the commercial and academic research being carried out in subsectors of healthcare. We analyse the short-, medium- and long-term prospects for stem cell breakthroughs in disease areas, providing the information that you require.

Our new report also provides a review of leading companies that currently seek to harness stem cell technologies. The research areas of each company are profiled, with discussion of the approaches being used. Some organisations are developing scalable therapies with allogeneic stem cells, while others investigate personalised treatments using autologous stem cells. Other organisations pursue research in the embryonic stem cells field, which has opened up in the US, with fewer obstacles and greater funding opportunities available since 2009. Some companies already generate revenues from stem cells by carving out market niches in stem cell supply, such as stem cells for drug development and toxicity assays, or services such as stem cell banking in umbilical cord blood. We analyse the main divisions of the market, providing revenue forecasts for 2010 to 2025.

Comprehensive analysis of the global stem cells market

Stem Cells - The Hype and the Hope 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are comprehensive tables and figures, as well as four interviews with experts. The result is a detailed market- and industry-centred study, with analyses and informed opinion to benefit your work.

Why you should buy Stem Cells - The Hype and the Hope 2010-2025

This report gives you the following benefits in particular:

• You will receive a comprehensive analysis of the prospects for stem cells from 2010 to 2025, including predicted revenues, growth rates and other data for the overall market and its main divisions

• You will find out where the market is heading - technologically and commercially - from the present onwards, both for the global market and for leading national markets

• You will discover prospects for leading companies and therapy areas, with predictions of where main breakthroughs are likely to come from 2010 to 2025

• You will identify significant R&D developments as well as up-and-coming technologies and products

• You will discover expert opinion from our interview-based survey, with discussion of the present and future of stem cells in medicine

• You will assess the commercial drivers, restraints, competition and opportunities influencing the global stem cell sector.

Our research shows that stem cells hold the potential to change medicine in decades to come, with benefits to healthcare stakeholders starting to appear during our forecast period, 2010 to 2025. We separate the real potential from the wishful thinking in this complex field.

You can obtain this report today

Nobody with an interest in healthcare biotechnology should overlook our new study on stem cells. We predict that revenue streams will commence and increase during our forecast period. With rising demand for novel therapies and many unmet clinical needs remaining, the stem cells industry and market hold potential for high revenues and continuous innovation. Do you want to be aware of those opportunities? You can stay ahead by ordering our new report today.

Table of Contents

1. Executive Summary

1.1 Stem Cells Market Review

1.2 Crucial Aspects of the Stem Cells Market

1.3 Aims, Scope and Format of this Report

1.3.1 Speculative Aspects of Assessing the Stem Cell Field

1.3.2 Chapter Outline

1.4 Research and Analysis Methods

2. Stem Cells: An Introduction

2.1 Stem Cells in 2010: Overview of the Sector

2.2 The Basics: What Are Stem Cells?

2.3 Stem Cell Potency

2.3.1 Totipotency

2.3.2 Pluripotency

2.3.3 Multipotency

2.3.4 Oligopotency

2.3.5 Unipotency

2.3.6 Stem Cells and Progenitor Cells

2.4 Embryonic Stem Cells

2.4.1 Abortion Debates, IVF, and Embryonic Stem Cells

2.4.2 Harvesting Human Eggs

2.5 Adult Stem Cells

2.5.1 Sources of Adult Stem Cells

3. Issues Affecting the Stem Cells Market, 2010

3.1 Strengths

3.1.1 Stem Cells Have Great Therapeutic Potential

3.1.2 Stem Cells Could Revolutionise Our Understanding of Disease

3.1.3 Animal Models Yield Impressive Results

3.1.4 Stem Cells Already Have Some Therapeutic Applications

3.1.5 The Stem Cells Field Has Strength in Numbers

3.1.6 Discoveries Are Being Made at a Rapid Rate

3.1.7 Adult Stem Cells: Fewer Ethical Controversies

3.1.8 Many Governments Support Adult Stem Cell Research

3.1.9 Stem Cells Have Proven Uses and Marketability Beyond Their Directly Therapeutic Applications

3.1.10 The Market Offers Multiple Business Models

3.2 Weaknesses

3.2.1 Therapies Take Time

3.2.2 Stem Cells and Cancer

3.2.3 The Safety-First Approach

3.2.4 Embryonic Stem Cell Supply Problems

3.2.5 Business Model Problems with Autologous Therapies

3.2.6 Donor Rejection Risk with Allogeneic Therapies

3.2.7 The Research Field is Fragmented

3.2.8 The IP Minefield

3.2.9 Government Money is Required: Little Venture Capital - Yet

3.2.10 Problems Adapting Pharmaceutical Business Model to Stem Cells

3.3 Opportunities

3.3.1 Therapies: Almost Anything Could Happen

3.3.2 The Attractions of the Stem Cells Market

3.3.3 Asia Harnesses Stem Cells Opportunities

3.3.3.1 China: Favourable Regulations

3.3.3.2 Japan: Liberal hESC Policy

3.3.3.3 Singapore: Advanced and Prominent

3.3.3.4 South Korea: Stem Cells a National Priority

3.3.3.5 India: First Official Research Hub Opened in 2009

3.3.3.6 Israel: at The Forefront

3.3.3.7 Gulf Countries: Funding Stem Cell Research

3.3.4 Adipose Tissue Opportunities for IPSCs

3.3.5 Beyond Pluripotency

3.3.6 Pharmaceutical Laws Do Not Apply to Stem Cell Therapies

3.3.7 Unique Disease Modelling Possibilities With IPS Cells

3.3.8 High Net-Worth Individuals: A Possible Source of Stem Cell Capital

3.3.9 The Opportunity to Get There First

3.3.10 Public Perception of Stem Cells Represents an Opportunity

3.4 Threats

3.4.1 The Risks of the Regulatory Environment

3.4.1.1 North America

3.4.1.2 Europe

3.4.2 Lack of Embryonic Stem Cell Diversity in US Research

3.4.3 Not Everyone Can Succeed in The Stem Cells Market

3.4.4 The Risk of Public Disenchantment

3.4.5 High-Profile Failures in Stem Cell Supply

3.4.6 High-Profile Failures in Stem Cell Therapies

3.4.7 Scare Stories and Perception Problems

3.4.8 Economic Instability

3.4.9 Market Fluidity is a Threat

3.4.10 Are Stem Cells Too Revolutionary for the Existing Pharmaceuticals Model?

4. The Stem Cell Market in 2010

4.1 The Stem Cell Market Was Worth Around $2.8bn in 2009

4.1.1 Where The Money is: Divisions of the Stem Cells Market in 2010

4.2 Stem Cell Therapies

4.2.1 Existing Stem Cell Therapies Market

4.2.2 Diseases Treated With Adult Stem Cells In 2010

4.2.3 Bone Marrow Transplants

4.2.3.1 The Transplant Process

4.2.3.2 The Results

4.2.4. Peripheral Blood Stem Cell Transplants

4.2.5 Cord Blood Stem Cell Transplants

4.2.6 Allogeneic Transplants vs. Autologous Transplants

4.2.6.1 Allogeneic Transplants are Better for Killing Cancer

4.2.6.2 The Problem with Allogenic Transplants: Graft-versus-Host Disease and Host-versus-Graft Disease

4.2.6.3 Saviour-Siblings: Stem Cells from a Sibling, Created or Chosen to be a Saviour

4.2.6.4 UK Cases and Rules on Saviour Siblings

4.2.7 Other Surgery Involving Stem Cells

4.2.8 Osteocel and other Bone Regeneration Products

4.2.9 Stem Cells and Regenerative Medicine

4.2.9.1 Organogenesis

4.2.9.2 Stem Cell Therapeutics

4.2.9.3 CEL-SCI Corporation

4.2.9.4 Osteotech

4.2.9.5 RegeneRx

4.2.9.6 RTI Biologics

4.2.9.7 Biomimetic Therapeutics

4.2.9.8 Fibrocell

4.2.10 Stem Cell Cosmetics

4.2.10.1 Breast Enhancement

4.2.10.2 Topical "Stem Cell" Preparations

4.2.11 Unregulated Stem Cells Therapies

4.3 Stem Cell Services

4.3.1 The Market for Stem Cell Services

4.3.2 Some of the Companies in the Stem Cell Services Market

4.3.2.1 Cellular Dynamics International: Cardiomyocyte Technology

4.3.2.2 Fate Therapeutics: Stem Cells for Drug Discovery

4.3.2.3 International Stem Cell Corporation: Parthenogenetic Cell Line Bank

4.3.2.4 Axiogenesis: Research Tools

4.3.2.5 Vitro Biopharma: Longer-Lasting Cell Line Expansion Periods

4.3.2.6 CellCyte Genetics: Expansion Bioreactor

4.3.2.7 MultiCell Technologies: Liver Stem Cell Lines

4.3.2.8 Stemgent: Stem Cell Scientists

4.3.2.9 Regenetech: Stem Cell Expansion Leaders

4.3.2.10 Pfizer/Novocell: Pancreatic Cell Lines

4.3.2.11 Biotime: 200+ Patent Portfolio

4.3.2.12 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?

4.3.2.13 Stem Cell Innovations (SCI): PluriCells Platform

4.3.2.14 HyClone/Thermo Fisher Scientific: 40 Years of Cell Culture Products

4.3.2.15 Merck/Calibochem/Stem Cell Sciences: Drug Screening Assays

4.3.2.16 Stemride International Limited (SIL) and Reproductive Genetics Institute, Chicago: Normal and Abnormal Cell Lines

4.3.2.17 ES Cell International, Singapore: Hoping for the First Marketed Product Including Embryonic Stem Cells

4.3.2.18 StemCell Technologies: ES Cells and Cell Culture Supplies

4.3.2.19 Bio-Matrix Scientific Group: Cryopreservation

4.4 Blood Banking

4.4.1 Biological Insurance: Private Blood Banking

4.4.2 Umbilical Cord Banking: The Controversies

4.4.2.1 US Oversight of Cord Blood Stem Cells

4.4.3 The Market for Blood Banking

4.4.4 Companies in the Field

4.4.4.1 Cord Blood America: Looking Towards the Chinese Market

4.4.4.2 ViaCord: 145,000 Blood Units in Storage

4.4.4.3 Cryo-Cell International: The First Cord Blood Bank

4.4.4.4 Stem Cell Authority: Exclusive Stem Cells

4.4.4.5 LifebankUSA: Placenta-Cord Banking

5. The New Stem Cell Therapies I: Companies and Business Models

5.1 In Search of a Stem Cells Business Model

5.1.1 Embryonic or Adult?

5.2 Stem Cell Companies in the Media Spotlight

5.2.1 Towards the First Human Trials of Embryonic Stem Cells

5.2.2 Adult Stem Cells: Collaborations with Pharmaceutical Giants

5.3 Embryonic Stem Cells

5.3.1 Geron: First Embryonic Stem Cell Trial

5.3.1.1 Geron and GE Healthcare

5.3.2 Advanced Cell Technology (ACT)

5.3.2.1 Competition for ACT in Macular Degeneration Treatment

5.3.2.2 ACT Deals with Other Companies

5.3.3 Novocell: Looking to Follow Geron and ACT in Embryonic Stem Cells Trials

5.3.3.1 Novocell's Collaborations with Pharmaceutical Leaders

5.3.4 CellCure Neurosciences

5.3.5 Royan Institute (Tehran)

5.3.6 Reliance Life Sciences, India

5.4 Adult Stem Cell Therapies: Allogeneic

5.4.1 Osiris: First to Market with Stem Cells

5.4.1.1 Osiris and NuVasive

5.4.1.2 Osiris and Genzyme

5.4.1.3 Prochymal: Great Promise but How is Work Shaping Up?

5.4.1.4 What Next for Prochymal?

5.4.2 Athersys

5.4.2.1 Multistem: an Off-The-Shelf Allogeneic Stem Cell Therapy

5.4.3 StemCells

5.4.4 MediStem (MediStem Laboratories, Inc.)

5.4.5 ReNeuron

5.4.6 Pluristem Therapeutics

5.4.7 Amstem International (Stem Cell Therapy International/Histostem)

5.4.8 Neuralstem

5.4.9 Garnet BioTherapeutics/Neuronyx

5.4.10 HepaLife Technologies

5.5 Adult Stem Cells: Autologous Therapies

5.5.1 Opexa Therapeutics

5.5.1.1 Tovaxin

5.5.2 Cellerix: Ontaril has EMEA Orphan Drug Status

5.5.3 Aastrom Biosciences

5.5.4 Bioheart

5.5.5 Cardiogenesis: Autologous Medical Devices

5.5.6 BrainStorm Cell Therapeutics

5.5.7 Cytori Therapeutics

5.5.8 TCA Cellular Therapy

5.5.9 Autologous Cell Storage

5.5.9.1 LifeStem: Two Sources of Stem Cells Preserved

5.5.9.2 Neostem: Success with Bone Marrow Stem Cell Storage

5.5.9.3 Thermogenesis: Autologous Cryopreservation

5.5.9.4 Biogenea-CellGenea: Leading Stem Cell Research Facility in the EU

6. The New Stem Cell Therapies II: Indications

6.1 The Growth of the Stem Cells Market to 2025

6.2 Near-Term Indications

6.2.1 Cancer

6.2.1.1 Cancer Stem Cells

6.2.2 Immune Disorders

6.2.3 Eye Diseases

6.2.4 Orthopaedics

6.2.5 Diabetes

6.2.6 Other Likely Near-Term Indications

6.2.6.1 Acute Radiation Syndrome

6.3 Cardiovascular Diseases

6.4 Brain and Central Nervous System Diseases

6.4.1 Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)

6.4.2 Multiple Sclerosis

6.4.3 Alzheimer's Disease

6.4.4 Cerebral Palsy

6.4.5 Pelizaeus-Merzbacher Disease (PMD)

6.4.6 Parkinson's Disease

6.4.7 Spinal Cord Injury

6.5 Growing Organs

6.6 Other Possible Indications for Stem Cells

6.6.1 Autism

6.6.2 HIV and Other Viral Diseases

6.6.3 Fertility Treatment

7. Interviews with Experts

7.1 Dr Johan Luthman, Merck Serono

7.1.1 Difficulties of Translational Medicine

7.1.2 Differences Between Technology and Media Perceptions

7.1.3 Confusion in the Media

7.1.4 Stem Cells and Neurologic Disorders

7.1.4.1 Which Neurological Disorders will be Treated First?

7.1.4.2 Multiple Sclerosis

7.1.5 Why Stem Cell Results Take a Long Time

7.1.6 When Stem Cell Therapies Will Reach the Market

7.1.7 The Distinction between Regenerative Medicine and Stem Cell Therapies

7.2 Dr Stephen Minger, Wolfson Centre for Age-Related Diseases, King's College London

7.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More Funding/Support

7.2.2 Cord Blood and Embryonic Stem Cells

7.2.3 The Need for More Immunological Assays

7.2.4 How Long Until there are Human Stem Cell Therapies?

7.2.5 Cord Blood as a Source of Stem Cells

7.2.6 Private Cord Blood Banking

7.2.7 Therapeutic Cloning

7.2.7.1 Therapeutic Cloning and Tissue Type Cell Lines

7.2.8 Promising and Unusual Immunological Properties of Embryonic Stem Cells

7.2.9 Mesenchymal Stem Cells and Inflammation

7.2.10 On the Use of Foreskin Fibroblasts

7.3 Gregory Bonfiglio, Proteus Venture Partners

7.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine"

7.3.2 On "Near Term" Applications

7.3.3 Value-Creation Curve for Venture Capital in Stem Cells

7.3.4 On There Being No Known Limits on Stem Cell Possibilities

7.3.5 On Stem Cells in 25 Years

7.3.6 Funding as a Primary Limitation?

7.3.7 Stem Cells in Multiple Sclerosis and Diabetes Type 1

7.3.8 Cord Blood

7.3.9 Extracellular Matrixes

7.3.10 Disease-Specific Cell Lines

7.3.11 Adult vs. Embryonic Stem Cells

7.3.12 Capital for Stem Cell and Regenerative Medicine Research

7.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE)

7.4.1 Embryonic Stem Cells and Dehumanisation

7.4.2 HFEA Regulation on Embryo Destruction

7.4.3 Economics and Scientific Effectiveness

7.4.4 Cord Blood

7.4.5 Adult Stem Cell Therapies and the Economics of Therapy

7.4.6 Public, Private and Private/Public Cord Blood Banks

7.4.7 International Studies and International Communication

8. Conclusions

8.1 The Stem Cell Market in 2010 is Small, But Will Grow Rapidly

8.2 The Stem Cell Therapies Market is on The Brink of Significant Growth

8.3 Induced Pluripotent Adult Stem Cells May Revolutionise the Market

8.4 The Sector Has Marked Uncertainties, But Many Opportunities

List of Tables

Table 2.1 Potency and Source of Stem Cells

Table 2.2 Germ Layers and Their Associated Types of Cells and Organs

Table 3.1 SWOT Analysis of the Stem Cells Sector, 2010

Table 4.1 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025

Table 4.2 Some Diseases That Have Been Treated With Adult Stem Cells, 2010

Table 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015

Table 4.4 Some Companies in the Regenerative Medicine Sector, 2010

Table 4.5 Stem Cell Services: Sales Forecast ($m), 2010-2025

Table 4.6 Some Companies in the Stem Cell Services Market, 2010

Table 4.7 Cord Blood Banking: Sales Forecast ($m), 2010-2025

Table 4.8 Some Companies in the Cord Blood Banking Market, 2010

Table 5.1 Some Companies in the Embryonic Stem Cell Therapies Sector, 2010

Table 5.2 Some Companies in the Allogeneic Adult Stem Cell Therapies Sector, 2010

Table 5.3 Some Companies in the Autologous Adult Stem Cell Therapies Sector, 2010

Table 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025

Table 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025

Table 8.1 Total Stem Cells Market: Sales Forecast by Sector ($m), 2010-2025

List of Figures

Figure 4.1 Sectors of the Stem Cells Market: Sales ($bn), 2009

Figure 4.2 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025

Figure 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015

Figure 4.4 Stem Cell Services: Sales Forecast ($m), 2010-2025

Figure 4.5 Cord Blood Banking: Sales Forecast ($m), 2010-2025

Figure 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025

Figure 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025 

Companies Listed

Aastrom Biosciences

Advanced Cell Technology

Aldagen

Alliance Technology Ventures

Amorcyte

AmStem International

Angioblast Systems

Anthony Nolan Trust

Assisted Human Reproductions Agency

AstraZeneca

Athersys

Australian Stem Cell Centre

Axiogenesis

AXM Pharma

Biogenea-CellGenea

Bioheart

Bio-Matrix Scientific Group

Biomimetic Therapeutics

BioTime

Boston Scientific Corporation

BrainStorm Cell Therapeutics

Bresagen

Burnham Institute for Medical Research, University of California

Calibochem

Canadian Institute of Health

Cardiogenesis Corp.

Casey Eye Institute

Cellartis

CellCure Neurosciences

CellCyte Genetics Corporation

Cellerix

Cellgene Corporation

Cellular Dynamics International

Cellular Engineering Technologies

Celprogen

CEL-SCI Corporation

Centocor Ortho Biotech

CHA Biotech

Children's Hospital of Orange County

Children's Hospital & Research Center in Oakland, California

Cleveland Clinic

Clinical Research Facility for Stem Cells and Regenerative Medicine, Hyderabad

Columbia University

Comment on Reproductive Ethics (CORE)

CorCell

Cord Blood America

Cord Blood Registry

Cordon Vital (CBR)

Cryo-Cell International

CyThera

Cytori Therapeutics

Diostech

Embryome Sciences

ES Cell International (Singapore)

European Medicines Agency (EMEA)

European Union Group on Ethics (EGE), The

EyeCyte

Fate Therapeutics

Fibrocell

Fisher Scientific

Foundation for Taxpayer and Consumer Rights, The

Gamida Cell

Garnet BioTherapeutics

GE Healthcare

Genzyme

Geron Corporation

Gladstone Institute of Cardiovascular Disease

GlaxoSmithKline

Hadasit Bio-Holdings

Hadassah University Hospital

Harvard Stem Cell Institute

Harvard University

HepaLife Technologies

Histostem

Human Fertilisation and Embryology Authority (HFEA, UK)

HyClone

Indiana University

International Society of Stem Cell Research

International Stem Cell Corporation

iPS Cells

Isolagen

Israeli Health Ministry

Johns Hopkins University

Johnson & Johnson

Korea Stem Cell Bank Co.

LifebankUSA

LifeCell India

Lifeline Cell Technology

LifeStem

London Breast Institute, Princess Grace Hospital

London Development Agency

London Regenerative Medicine Network (LRMN)

Maxim Biotech

Mayo Clinic

MedCell Biosciences

Medical College of Georgia

Medistem

Merck & Co.

Merck KGaA

Merck Serono

Mesoblast

Multicell Technologies

Muslim World League

Mytogen

NASA

National Institutes of Health (NIH, US)

National Health Service (NHS, UK)

National Tissue Engineering Center (Shanghai)

Neostem

Neuralstem

Neuronyx

Northwestern University

Novartis

Novartis Institutes for BioMedical Research (NIBR)

Novo Nordisk

Novocell

NuVasive

Opexa Therapeutics

Organogenesis

Orthofix

Osiris Therapeutics

OST Developpement

Osteotech

Patient Patent Foundation

Pfizer

Pluristem Therapeutics

Primogenix

ProLife Alliance, The

Proteus Venture Partners

Purdue University Indianapolis

Reeve-Irvine Research Centre

Regenetech

RegenRx

Reliance Life Sciences, India

ReNeuron

Reproductive Genetics Institute (Chicago)

RNL Bio

Roche

Royal Veterinary College, The

Royan Institute (Tehran)

RTI Biologics

Rutgers University

Safeguard Scientifics

SCP Vitalife Partners

Singapore Stem Cell Consortium

Stanford University

Stem Cell & Regenerative Medicine International

Stem Cell Authority

Stem Cell Innovations (SCI)

Stem Cell Products

Stem Cell Sciences

Stem Cell Therapeutics Corp.

Stem Cell Therapy International

Stem Cells Research Forum of India (SCRFI)

StemCell Technologies

StemCells

StemCells

Stemgent

StemLifeLine

Stemride International Limited (SIL)

SUNY Upstate Medical University

Suzhou Erye Pharmaceuticals

TCA Cellular Therapy

Tengion

Texas A&M University

The Food and Drug Administration (FDA)

Thermo Electron

Thermo Fisher Scientific

Thermogenesis Corp.

Transition Holdings

U.S. Army Institute of Surgical Research (USAISR)

U.S. Department of Defense

United States of America Patent and Trademark Office

University College London

University of Amsterdam

University of California at Irvine

University of California at San Diego

University of Edinburgh

University of Florida

University of Helsinki

University of Kyoto

University of Miami

University of Michigan

University of Oklahoma

University of Pittsburgh

University of South Florida

University of Texas, Medical Branch at Galveston

University of Virginia

University of Wisconsin

UT Southwestern Medical Center

Vantus

Veritas Corporation

VetCell Bioscience Limited

VetStem

ViaCord

Vitro Biopharma

Vitro Diagnostics

Voss Laboratories

Wake Forest University

Wisconsin Alumni Research Foundation (WARF)

Wolfson Centre for Age-Related Diseases (part of King's College, University of London) 

To order this report:

Biotechnology Industry: Stem Cells - The Hype and the Hope 2010-2025

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker